- The Wall Street Journal•3 hours ago
U.S. health regulators have rejected a promising rheumatoid arthritis treatment being developed jointly by Sanofi and Regeneron Pharmaceuticals over deficiencies found at a French plant, the companies ...
- Investor's Business Daily•5 hours ago
Sanofi and Novo Nordisk diverged Friday on differing outlooks for the U.S. insulin market as AbbVie toppled on its Q3 sales miss.
- Reuters•5 hours ago
Sanofi SA and Regeneron Pharmaceuticals Inc on Friday said U.S. regulators had declined to approve their experimental treatment for rheumatoid arthritis because of manufacturing deficiencies. The companies, in a release, said the U.S. Food and Drug Administration identified the deficiencies during a routine inspection of a Sanofi plant in France where the drug, sarilumab, is filled and finished, one of the last steps in the manufacturing process. Sanofi said it had submitted a comprehensive correction plan to the FDA and is taking corrective actions.
NYSE - NYSE Delayed Price. Currency in USD
|Bid||38.00 x 200|
|Ask||39.20 x 100|
|Day's Range||38.40 - 39.37|
|52wk Range||36.81 - 50.95|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||22.20|
|Avg Vol (3m)||2,339,132|
|Dividend & Yield||1.66 (4.49%)|